CELC Stock Summary and Trading Ideas (Celcuity | NASDAQ:CELC)

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Celcuity trades on the NASDAQ stock market under the symbol CELC.

As of April 24, 2024, CELC stock price declined to $16.94 with 87,944 million shares trading.

CELC has a beta of 1.41, meaning it tends to be more sensitive to market movements. CELC has a correlation of 0.12 to the broad based SPY ETF.

CELC has a market cap of $427.53 million. This is considered a Small Cap stock.

In the last 3 years, CELC stock traded as high as $33.01 and as low as $4.81.

The top ETF exchange traded funds that CELC belongs to (by Net Assets): VTI, IWM, VXF, DWAS, IWN.

CELC has outperformed the market in the last year with a return of +74.8%, while the SPY ETF gained +24.2%. In the last 3 month period, CELC beat the market returning +11.2%, while SPY returned +4.6%. However, in the most recent 2 weeks CELC has underperformed the stock market by returning -14.9%, while SPY returned -2.7%.

CELC support price is $16.60 and resistance is $17.89 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CELC stock will trade within this expected range on the day.